Precision Oncology Advances in 2020 – Looking Ahead to 2021!
February 16, 2021
1-3:30 P.M. ET
Anna D. Barker, Ellison Institute for Transformative Medicine at USC, Los Angeles, California
Antoni Ribas, University of California Los Angeles (UCLA), Jonsson Comprehensive Cancer Center (JCCC), Los Angeles, California
Bob Riter, AACR Scientist↔Survivor Program®, Ithaca, New York
John L. Marshall, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
Elizabeth M. Jaffee, Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland
David Spetzler, Caris Life Sciences, Phoenix, Arizona
The COVID-19 pandemic dominated headlines in 2020. The response by the research community was marked by unprecedented scientific collaboration and rapid research advances culminating in the authorization of two vaccines against SARS-CoV-2, less than 12 months after the first reported COVID cases.
But there were also a number of advances made in cancer research that should be highlighted as we look forward to 2021. Most notably in new targeted agents, advanced diagnostic technologies, and a renewed commitment to increase public understanding of cancer health disparities. A number of cancer communities also saw years of commitment to cancer research pay off with a record number of drug approvals.
This Virtual AACR Patient Advocate Forum highlights some of the recent breakthroughs in cancer research and showcase what we might be able to expect in the year 2021.Program Agenda speaker bios